56
Under the agreement, Schlieren-based LimmaTech Biologics AG receives the exclusive rights from Abbvacc Inc, a recent spin-out from Integrated Biotherapeutics (IBT) LLC, to conduct Phase I clinical trials with AbVacc Inc’s six-valent S. aureus toxoid vaccine candidate LBT-SA7 (IBT-V02) to prevent hospital-acquired infections with the multidrug-resistant bacterium. LimmaTech plans to initiate Phase 1 clinical development of the the first entirely non-surface antigen-based S. aureus vaccine in 2024 with an option to acquire full worldwide rights after the trial readout. Financial details of the deal such as upfront and milestone payment were not…